Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

May 29, 2020

SEATTLE--(BUSINESS WIRE)--May 29, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR 2020 E-Congress, taking place virtually June 3-6, 2020.

Details of the presentations are as follows:

  • Presentation Title: B Cell Modulatory Variant TNF Receptor Domains (vTDs) Identified by Directed Evolution to Inhibit BAFF and APRIL, Alone or Combined with Variant Ig Domains (vIgD™) that Inhibit T Cell Costimulation, for the Treatment of Severe Autoimmune and/or Inflammatory Disease
  • Session Title: New perspectives: Mechanisms driving SLE, Sjögren's and APS
  • Dates and Times: Thursday, June 4, 2020, 11:50 - 13:30
  • Presentation Location: Virtual Meeting
  • Session Type: Poster Tour
  • Poster Number: THU0222
  • Presentation Title: A Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, in Healthy Volunteers (HV)
  • Session Title: SLE, Sjögren's and APS - Treatment
  • Dates and Times: Saturday, June 6, 2020, 10:30 - 12:00
  • Presentation Location: Virtual Meeting
  • Session Type: Poster View
  • Poster Number: SAT0196

An abstract of the presentation will be available on the EULAR E-Congress 2020.

About ALPN-101

ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™), a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease, and multiple sclerosis, ALPN-101 demonstrates efficacy superior to agents blocking the CD28 - CD80/86 and/or ICOS - ICOSL pathways alone. A phase 1b/2 trial of ALPN-101 in acute GVHD (BALANCE, NCT04227938) has been initiated.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients’ lives via unique protein engineering technologies. Alpine has two programs in clinical development. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation antagonist engineered to reduce pathogenic T and B cell immune responses by inhibiting ICOS and CD28. ALPN-101 has recently completed enrollment of a phase 1 healthy volunteer study, and BALANCE, a phase 1b/2 study in acute GVHD, has recently been initiated. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor, and enrollment is open in NEON-1, a phase 1 study in advanced malignancies. Alpine is backed by world-class research and development capabilities, a highly productive scientific platform, and a proven management team. For more information, visit

Paul Rickey
Chief Financial Officer
Alpine Immune Sciences, Inc.
[email protected]

Laurence Watts
Managing Director
Gilmartin Group, LLC.
[email protected]

Source: Alpine Immune Sciences Inc.